Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Corgard
Overview
What is Corgard?
CORGARD (nadolol) is a synthetic nonselective beta-adrenergic receptor blocking agent designated chemically as 1-(-butyl-amino)-3-[(5,6,7,8-tetrahydro--6,7-dihydroxy-1-naphthyl) oxy]-2-propanol. Structural formula:
Nadolol is a white crystalline powder. It is freely soluble in ethanol, soluble in hydrochloric acid, slightly soluble in water and in chloroform, and very slightly soluble in sodium hydroxide.
CORGARD (nadolol) is available for oral administration as 20 mg, 40 mg, and 80 mg tablets. Inactive ingredients: microcrystalline cellulose, colorant (FD& C Blue No. 2), corn starch, magnesium stearate, povidone (except 20 mg and 40 mg), and other ingredients.
What does Corgard look like?





What are the available doses of Corgard?
Sorry No records found.
What should I talk to my health care provider before I take Corgard?
Sorry No records found
How should I use Corgard?
CORGARD (nadolol) is indicated for the long-term management of patients with angina pectoris.
DOSAGE MUST BE INDIVIDUALIZED. CORGARD (NADOLOL) MAY BE ADMINISTERED WITHOUT REGARD TO MEALS.
What interacts with Corgard?
Nadolol is contraindicated in bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see ).
What are the warnings of Corgard?
Cardiac Failure
Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.
IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or nadolol should be discontinued (gradually, if possible).
Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.
Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)
PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Nadolol should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta receptors.
Major Surgery
Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.
Diabetes and Hypoglycemia
Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs.
Thyrotoxicosis
Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm.
What are the precautions of Corgard?
Impaired Renal Function
Nadolol should be used with caution in patients with impaired renal function (see ).
Information for Patients
Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of nadolol therapy without the physician's advice. Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure. The patient should also be advised of a proper course in the event of an inadvertently missed dose.
Drug Interactions
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents:
Anesthetics, general
Antidiabetic drugs (oral agents and insulin)
Catecholamine-depleting drugs (e.g., reserpine)
Digitalis glycosides
Response to Treatment for Anaphylactic Reaction
Carcinogenesis, Mutagenesis, Impairment of Fertility
In chronic oral toxicologic studies (one to two years) in mice, rats, and dogs, nadolol did not produce any significant toxic effects. In two-year oral carcinogenic studies in rats and mice, nadolol did not produce any neoplastic, preneoplastic, or non-neoplastic pathologic lesions. In fertility and general reproductive performance studies in rats, nadolol caused no adverse effects.
Pregnancy
In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits, but not in rats or hamsters, at doses 5 to 10 times greater (on a mg/kg basis) than the maximum indicated human dose. No teratogenic potential was observed in any of these species.
There are no adequate and well-controlled studies in pregnant women. Nadolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates whose mothers are receiving nadolol at parturition have exhibited bradycardia, hypoglycemia, and associated symptoms.
Nursing Mothers
Nadolol is excreted in human milk. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the importance of CORGARD (nadolol) to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
What are the side effects of Corgard?
Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.
Cardiovascular
Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also , , and ).
Central Nervous System
Dizziness or fatigue has been reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior have each been reported in approximately 6 of 1000 patients.
Respiratory
Bronchospasm has been reported in approximately 1 of 1000 patients (see and ).
Gastrointestinal
Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence have been reported in 1 to 5 of 1000 patients.
Miscellaneous
Each of the following has been reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Reversible alopecia has been reported infrequently.
The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.
Central Nervous System
Reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability with slightly clouded sensorium, and decreased performance on neuropsychometrics.
Gastrointestinal
Mesenteric arterial thrombosis; ischemic colitis; elevated liver enzymes.
Hematologic
Agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura.
Allergic
Fever combined with aching and sore throat; laryngospasm; respiratory distress.
Miscellaneous
Pemphigoid rash; hypertensive reaction in patients with pheochromocytoma; sleep disturbances; Peyronie's disease.
The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with nadolol.
What should I look out for while using Corgard?
Nadolol is contraindicated in bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see ).
What might happen if I take too much Corgard?
Nadolol can be removed from the general circulation by hemodialysis.
In addition to gastric lavage, the following measures should be employed, as appropriate. In determining the duration of corrective therapy, note must be taken of the long duration of the effect of nadolol.
How should I store and handle Corgard?
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet. Repackaged By:Cardinal HealthZanesville, OH 43701L49929540815CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.CORGARD Tablets (Nadolol Tablets USP) are available in bottles of 100 in the following strengths:20 mg tabletsNDC40 mg tabletsNDC80 mg tabletsNDCAll tablets are scored (bisect bar) and easy to break. USWM is imprinted above the bisect bar.